Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Target Molecule
100%
Degrader
100%
Degradation Pathway
100%
SUMO2
100%
TOPORS
100%
RNF4
100%
SUMO1
100%
Arsenic
100%
Promyelocytic Leukemia
100%
Ubiquitination
75%
Bromodomain-containing Protein 4 (BRD4)
75%
Lysine
50%
Ubiquitin
25%
RING E3 Ligase
25%
Ubiquitinome
25%
Small Molecule Degrader
25%
In Vitro Ubiquitination Assay
25%
Therapeutic Potential
25%
Optimal Position
25%
Cryo-EM Structure
25%
Therapeutic Efficacy
25%
Nucleophilic Attack
25%
Targeted Degradation
25%
Cell Degradation
25%
Ternary Complex
25%
Long-lived
25%
Cullin2
25%
Rational Drug Design
25%
Mass Spectrometry
25%
Conjugation
22%
Oncogenic Fusion Protein
11%
Missense mutation
11%
Clinical Relapse
11%
SUMOylation
11%
Ubiquitin-mediated Degradation
11%
Ubiquitin Ligase
11%
Resistant Disease
11%
Acute Promyelocytic Leukemia
11%
Arsenic Resistance
11%
Induced Degradation
11%
Retinoic Acid Receptor
11%
Leukemia Cells
11%
Polyubiquitin
11%
Biochemistry, Genetics and Molecular Biology
Ubiquitination
100%
SUMO2
100%
Ubiquitin
58%
Ubiquitin Ligase
58%
Lysine
50%
Sumoylation
33%
P97
33%
Wild Type
33%
Carcinogenesis
33%
Missense Mutation
33%
Chimeric Protein
33%
Retinoic Acid Receptor Alpha
33%
Cullin
25%
Nucleophilicity
25%
Mass Spectrometry
25%
Ternary Complex
25%
Small Molecule
25%
Cryoelectron Microscopy
25%
Pharmacology, Toxicology and Pharmaceutical Science
Promyelocytic Leukemia
100%
Diseases
10%
Ubiquitin
10%
Ubiquitin Protein Ligase
10%
Polyubiquitin
10%
Chimeric Protein
10%
Carcinogenesis
10%
Retinoic Acid Receptor Alpha
10%